Answers are grounded in this paper and cite their sources.
Extranodal NK/T-cell lymphoma (ENKTL) is an Epstein–Barr virus (EBV)-driven malignancy concentrated in East Asia and Latin America. Central nervous system (CNS) involvement occurs in 1.3–5.8% of largely unselected cohorts and carries a median survival of a few months. It has been reviewed only within broader T-cell scopes, never with ENKTL as the subject, although ENKTL is the only subtype in that lineage with its own validated CNS relapse model. Cohorts of more than 4500 patients support four observations. Incidence estimates are barely comparable because the CNS endpoint differs in almost every study; the reported range probably understates the true burden through incomplete cerebrospinal fluid (CSF) ascertainment. Meanwhile, two competing-risk analyses indicate that truncation of the observation window conceals little. Risk is concentrated in a definable subgroup: CNS-PINK, a two-point index for NK-cell lymphoma, separates a high-risk group with 2-year CNS relapse of 13.9–22.8% from a low-risk group at 4.1–4.5%, yet it assigns no patient with localized disease to that group, and a pan-T/NK model (CITI) did not select ENKTL as a risk histology. Prophylaxis evidence is internally inconsistent: the only positive signal, systemic intermediate-dose methotrexate, came from one training cohort and did not reach significance on validation, against uniformly conservative guidelines. Diagnosis is shifting from cytology toward CSF flow cytometry and circulating tumor DNA. Prophylaxis can neither be recommended nor withheld on current evidence; for each of the three decisions, we set out what the literature reaches and how far.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: